Company profile: Carrick Therapeutics
1.1 - Company Overview
Company description
- Provider of cancer therapeutics targeting molecular pathways driving aggressive and resistant cancers. Pipeline includes Samuraciclib (CT7001), an oral CDK7 inhibitor in clinical development for HR+, HER2- advanced breast cancer and triple negative breast cancer, and a CDK12/13 inhibitor/Cyclin-K glue-degrader in IND enabling toxicology studies targeting genomic stability and DNA repair.
Products and services
- CDK12/13 inhibitor / Cyclin-K glue-degrader: IND-enabling therapy that targets genomic stability and DNA repair in cancer with a Cyclin-K glue-degrader mechanism, currently undergoing toxicology studies
- Predictive biomarker detection: Biomarker-guided service enabling cancer patients to get predictive biomarkers detected to guide treatments, leveraging innovative mechanisms targeting aggressive and resistant disease pathways
- Samuraciclib (CT7001): Clinical-stage oral CDK7 inhibitor developed to treat HR+, HER2- advanced breast cancer and triple negative breast cancer by targeting molecular pathways driving aggressive, resistant tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Carrick Therapeutics
Lycia Therapeutics
HQ: United States
Website
- Description: Provider of lysosome-targeting chimeras (LYTAC) technology for developing therapeutics that target and degrade extracellular and membrane-bound proteins for a range of diseases. Offers the LYTAC platform and a discovery pipeline of degraders for autoimmune and inflammatory conditions and cancer, and maintains a strategic collaboration with Lilly focused on immunology and pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lycia Therapeutics company profile →
Galil Medical
HQ: United States
Website
- Description: Provider of minimally invasive cryotherapy technology and systems for various clinical applications, using compressed Argon gas to freeze and ablate diseased tissue in procedures referred to as cryotherapy, cryoablation, or cryosurgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galil Medical company profile →
Arius Research
HQ: Canada
Website
- Description: Provider of biotechnology solutions centered on the discovery and development of antibody therapeutics, primarily targeting breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma, leveraging its FunctionFIRST platform to identify monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arius Research company profile →
Photocure
HQ: United States
Website
- Description: Provider of photodynamic specialty pharmaceuticals, including Hexvix/Cysview to improve bladder tumor detection and resection via Blue Light Cystoscopy, and Cevira, a photodynamic drug-device for non-surgical treatment of cervical HSIL; also supports patient registries and real-world evidence in bladder cancer. Norwegian-based.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Photocure company profile →
Zap Surgical
HQ: United States
Website
- Description: Provider of the ZAP-X gyroscopic radiosurgery platform for treating brain tumors, lesions, and head and neck conditions, utilizing a modern linear accelerator that eliminates radioactive source replacements. Offers vault-free design to reduce infrastructure costs, dual independent gantries for >1000 non-coplanar beam angles, tungsten-shielded collimation, and SRS webinars and clinical publications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zap Surgical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Carrick Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Carrick Therapeutics
2.2 - Growth funds investing in similar companies to Carrick Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Carrick Therapeutics
4.2 - Public trading comparable groups for Carrick Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →